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Carlos Lapresta4, Rosario Menendez5 and Antoni Torres6Abstract
Background: The role of mixed pneumonia (virus + bacteria) in community-acquired pneumonia (CAP) has been
described in recent years. However, it is not known whether the systemic inflammatory profile is different compared
to monomicrobial CAP. We wanted to investigate this profile of mixed viral-bacterial infection and to compare it to
monomicrobial bacterial or viral CAP.
Methods: We measured baseline serum procalcitonin (PCT), C reactive protein (CRP), and white blood cell (WBC)
count in 171 patients with CAP with definite etiology admitted to a tertiary hospital: 59 (34.5%) bacterial, 66 (39.%)
viral and 46 (27%) mixed (viral-bacterial).
Results: Serum PCT levels were higher in mixed and bacterial CAP compared to viral CAP. CRP levels were higher
in mixed CAP compared to the other groups. CRP was independently associated with mixed CAP. CRP levels below
26 mg/dL were indicative of an etiology other than mixed in 83% of cases, but the positive predictive value was
45%. PCT levels over 2.10 ng/mL had a positive predictive value for bacterial-involved CAP versus viral CAP of 78%,
but the negative predictive value was 48%.
Conclusions: Mixed CAP has a different inflammatory pattern compared to bacterial or viral CAP. High CRP levels
may be useful for clinicians to suspect mixed CAP.
Keywords: Community-acquired pneumonia, Viral pneumonia, BiomarkersBackground
Viruses have only become known as a microorganism
involved in CAP in the adult immunocompetent popula-
tion in recent years. Available data show that a virus is
the only microorganism isolated in between 10% and
30% of immunocompetent adults hospitalized for CAP,
and accounts for as much as 40% of cases with established
etiology. A bacterium as a co-pathogen of a virus can be
found in association with CAP (mixed viral-bacterial
pneumonia) [1-4] and this accounts for as much as 39% of
cases in which an etiological agent is identified [1-3]. In
these studies, Streptococcus pneumoniae continues to be
the most frequent producer of adult CAP, though
frequently in association with a co-pathogen, especially
viruses (20%-40%) [2,3,5,6]. It seems logical that, due to* Correspondence: sbello@salud.aragon.es
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unless otherwise stated.the lower sensitivity of techniques usually employed to
diagnose bacterial infection, some pneumonias considered
to be viral will actually be mixed CAP [3]. This issue, to-
gether with the possible isolation of viruses from asymp-
tomatic subjects, suggesting clearance of a past or current
subclinical upper airway infection not related to a con-
comitant CAP, has led to uncertainty as to whether some
viruses are the real cause of CAP or whether they must
act as a co-pathogen with a bacteria in adults [2,3,6-8]; the
generally accepted opinion is that viruses other than influ-
enza rarely cause pneumonia in healthy adults [9].
Besides individual host responses, there is increasing
evidence that several different causal microorganisms
may trigger different inflammatory responses, and levels
of several markers such as white blood cells (WBC), C-
reactive protein (CRP) and procalcitonin (PCT) are asso-
ciated with different etiological patterns [10,11]. Clinical
signs and symptoms of bacterial and viral pneumonia
are highly variable and overlap, and there is no clinicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the two causes of CAP [12]. Some attempts at differenti-
ation based on biomarkers have been made, and it is
now well established that CRP and, especially, PCT show
higher levels in bacterial than in viral (or atypical) pneu-
monia [12-14]. Lack of viral PCT response to viral infec-
tion is thought to be related to post-infection release of
interferon, which inhibits PCT synthesis [15].
There are very few studies of mixed viral-bacterial CAP
that involve biomarkers. The only available data concern
H1N1 influenza, from retrospective studies with a limited
number of patients, mostly in those admitted to the ICU,
showing increased PCT [16-19] and CRP [18,19] levels in
bacterial coinfection; this suggests that the biomarkers
may be used as a tool for discriminating mixed CAP from
H1N1 viral CAP. The CAPNETZ study included a large
number of patients (1337) with CAP, of which 58 (4.3%)
showed mixed etiologies; however, this group was hetero-
geneous, as it included two or more typical or atypical
bacteria and combinations of typical with atypical and any
bacteria with a virus [10].
We wanted to determine WBC, CRP and PCT levels
in mixed viral-bacterial CAP, and wondered whether
biomarkers in mixed disease showed a different pattern
than in either bacterial or viral CAP alone.Methods
Ethics statement
This study received written approval from the Instituto
Aragonés de Ciencias de la Salud (IACS) review board.Study design
From February 2009 to December 2010 (22 months),
consecutive adult (>18 years) patients admitted to a uni-
versity hospital with a diagnosis of CAP were prospect-
ively recruited within 24 hours of their arrival. CAP was
defined as an acute disease with a new radiologic infiltrate
not due to another known cause, in association with symp-
toms of lower respiratory-tract infection. Exclusion criteria
were severe immunodepression (HIV infection, severe
hematological disease); immunosuppressive therapy (pred-
nisone or equivalent daily dose of >20 mg for >2 weeks), or
any immunosuppressive regimen (azathioprine, cyclospor-
ine, cyclophosphamide and/or other immunosuppressant
drugs); leucopenia < 1000/mm3 or neutropenia <500/mm3
and/or chemotherapy in the previous year; pulmonary
abscess (x-ray cavitation), aspiration pneumonia and ob-
structive pneumonia; possible nosocomial origin (less than
30 days after hospital discharge); and known active neopla-
sia. The study was approved by the ethics committee and
all patients signed an informed consent form. All patients
were followed up during their hospital stay and those with
a definitive diagnosis other than CAP were excluded.Throughout the study period, a sex-matched and age-
matched control group was collected from subjects admit-
ted to the orthopedic-surgery, digestive medicine, and
neurology departments. None of these patients had had
any suspected infectious or respiratory disease in the pre-
vious two months, immunosuppression, known neoplasia,
or recent trauma, and none had recently undergone surgi-
cal procedures. The objectives of this control group were
to determine the false positive rate of our viral PCR tech-
niques in the same period than our CAP group, as well as
to compare biomarker levels in both populations.
The following variables were recorded: age, sex,
anti-influenza vaccination <1 year, antipneumococcal
vaccination <5 years, tobacco (non-smoker, ex-smoker,
pack-years) alcohol (non-drinker, ex-drinker, current
drinker [<80 g/day, >80 g/day]), comorbidities, previous
pneumonia, recent (1 month) antibiotic treatment. On
admission: days of duration of disease, symptoms prior
to infection, myalgia, CAP signs and symptoms, vital
constants on admission to the emergency department
(ED) (respiratory and heart rates, arterial pressure,
SaO2), number of hours in the ED, arterial blood gas
determinations (when performed), number of lobes
involved and type of x-ray condensation (alveolar, inter-
stitial, mixed), and pneumothorax/atelectasis/bleeding.
Pneumonia Severity Index (PSI) and the severity score
from British Thoracic Society (CURB65) were calculated
for all patients. All patients were admitted to hospital
for at least 24 hours.
Determination of leukocyte count, CRP and PCT
Venous blood samples were collected from CAP patients
and controls on admission to the ED, within 6 hours of ar-
rival. A sample was submitted to the hematology lab for a
WBC count, and another sample with EDTA was submit-
ted to the biochemistry lab for CRP and PCT assessment.
These latter samples were centrifuged and stored at −80°C
until biomarker tests were performed. Serum CRP was
measured by means of immunoturbidimetry using the
highly sensitive near-infrared particle immunoassay
(NIPIA) method (IMMAGE 800, BeckmanCoulter, San
Diego, USA). The assay has an analytical detection limit
of 0.06 mg/L and a functional assay sensitivity of
0.11 mg/L. Procalcitonin concentrations were deter-
mined using sandwich immunoassays and time-resolved
amplified cryptate emission (TRACE) measurement (PCT
sensitive KRYPTOR, BRAHMS, Hennigsdorf, Germany),
as described in detail previously [20]. The analytical
detection limit and the functional assay sensitivity for
the assays were 0.02 ng/mL and 0.06 ng/mL, respect-
ively, for procalcitonin. Measurements of PCT were
performed in our laboratory in a blinded fashion with-
out knowing the clinical parameters and microbio-
logical results.
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Blood was drawn from CAP patients in the ED shortly
after CAP diagnosis for bacterial culture. Sputum was
obtained when possible and before antibiotics were ad-
ministered, and immediately sent for Gram staining and
culture; only samples containing a preponderance of leu-
kocytes and a few squamous epithelial cells were consid-
ered acceptable. Another blood sample was obtained for
Mycoplasma pneumoniae (Complement Fixation test, Vir-
ion Serion Institut, Würzburg, Germany) and Chlamydo-
phila pneumoniae (ELISA test, Savyon Diagnostics Ltd, St.
Ashdod, Israel) first serum test. Second serological tests
were performed on blood obtained during the 30-day
follow-up visit, when possible. Urine was taken in the first
24 hours and tested for Streptococcus pneumoniae and
Legionella pneumophila antigens (BINAX now, Binax,
Portland, ME, USA).
Nasopharyngeal aspirate was obtained and processed
for viral antigens using the direct fluorescence antibody
(DFA) assay, and two different polymerase chain reac-
tion (PCR) viral tests. DFA was performed for influenza
A and B, parainfluenza 1, 2 and 3, adenovirus (ADV),
human metapneumovirus (hMPV) and respiratory syn-
cytial virus (RSV) (D3 Double Duet DFA RespiratoryFigure 1 Flow diagram for patient enrollment or exclusion in the stud
those with no comprehensive microbiological study, those with a final diag
diagnosis, we obtained 185 patients with CAP and isolation of at least 1 m
bacteria-involved CAP, all of which were Mycoplasma pneumoniae (1 M pn
influenza A + influenza B + syncytial respiratory virus [RSV], and 1 M pneum
CAP cause because of their low pathogenicity (2 from bacterial group [1 En
(2 S. hominis + Adenovirus, 1 S. hominis + Virus influenza A + RSV, 1 Staphy
morgagnii + coronavirus]). We then had 174 patients with viral, bacterial an
three patients, and we finally included 171 patients in our study with bothvirus screening and ID Kit, Diagnostic Hybrids, Athens,
USA). The first PCR was a multiplex RT-nested PCR
assay for 14 respiratory viruses (influenza A, B and C,
respiratory syncytial virus A and B, adenovirus, corona-
virus 229E and OC43, enterovirus, parainfluenza 1, 2, 3
and 4, and rhinovirus) [21]; the second test was a RT-
PCR commercial kit, the ResPlex II Plus Panel (Qiagen
LiquiChip System, Hamburg, Germany) [22] for detection
of 18 viruses: influenza A and B, RSV A and B, parainflu-
enza 1, 2, 3 and 4, hMPV A and B, enterovirus (coxsackie/
echovirus), rhinovirus, adenovirus B and E, coronavirus
NL63, HKU1, 229E and OC43, and bocavirus. Nucleic
acids were extracted from nasopharyngeal aspirates imme-
diately after their reception.
After excluding atypical-involved CAP (M pneumoniae
and C pneumoniae), patients with CAP were divided
into 3 groups: bacterial, viral and mixed. Patients with
no microbiological findings were considered as CAP of
unknown cause.
S pneumoniae, other potentially pathogen gram-positive
and gram-negative bacteria classically considered pro-
ducers of CAP (Haemophilus influenzae, Moraxella catar-
rhalis, Staphylococcus aureus, etc.) and L pneumophila,
were included in the group of “bacterial” CAP. One ory. After excluding patients who did not meet the inclusion criteria,
nosis other than CAP, and those with negative microbiological
icroorganism. We subsequently excluded 4 patients with atypical
eumoniae + E coli, 1 M pneumoniae + influenza A, 1 M pneumoniae +
oniae isolated), and a further 7 due to a bacterial yield of improbable
terococcus faecalis and 1 Staphylococcus hominis) and 5 from mixed
lococcus coagulase-negative +metapneumovirus, and 1 Morganella
d mixed pneumonia. A biomarker search could not be performed in
etiology and biomarkers.
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with one or more virus were considered as mixed CAP.
Viral CAP was defined as a CAP with detection of a
virus and no isolation of bacteria or atypicals. Overall
viral and bacterial was the result of adding viral andTable 1 Baseline characteristics of the 171 cases of communit
Characteristic
Age, years
>65 years
Male sex
Smoking status Yes
No
Ex-smoker
Previous antibiotic
Concomitant illnesses Neoplastic disease (not active)
Heart disease
Cerebrovascular disease
COPD
Liver disease
Renal disease
Diabetes mellitus
Bronchiectasis
No first pneumonia
Clinical findings Duration of symptoms prior to enrolment
(mean no. of days)
Altered mental status
Pulse > 125/min
Respiratory rate > 30/min
Systolic BP < 90 mmHg or diastolic BP < 60 m
Temperature < 35°C or > 40°C
Radiographic findings Unilobar involvement
Multilobar/bilateral involvement
Pleural effusion
PSI Mean PSI score
Class 1-3
Class 2-5
CURB65 0-1
2-5
Symptoms Fever
Cough
Expectoration
Dyspnea
Pleuritic pain
Digestive
Headache
Myalgiabacterial groups of CAP. Bacterial-involved was the
addition of mixed (bacterial and viral) and bacterial CAP.
Both positive microbiological findings and biomarker test
were required to include patients in the study group
(Figure 1).y-acquired pneumonia included in the study
Bacterial n = 59 Viral n = 66 Mixed n = 46 p
72 (14) 76 (17) 72 (20) NS
42 (70%) 50 (75.76%) 32 (68.09%) NS
42 (70%) 40 (60.61%) 23 (48.94%) NS
16 (27.12%) 11 (16.67%) 9 (19.15%) NS
17 (28.81%) 33 (50%) 22 (46.81%) NS
26 (44.07%) 22 (33.33%) 16 (34.04%) NS
12 (20%) 16 (24.24%) 6 (12.77%) NS
7 (11.67%) 10 (15.15%) 5 (10.64%) NS
25 (41.67%) 23 (34.85%) 14 (29.79%) NS
11 (18.33%) 14 (21.21%) 7 (14.89%) NS
21 (35%) 19 (28.79%) 12 (25.53%) NS
2 (3.33%) 2 (3.03%) 1 (2.13%) NS
6 (10%) 9 (13.64%) 5 (10.64%) NS
11 (18.33%) 15 (22.73%) 6 (12.77%) NS
5 (8.33%) 1 (1.52%) 2 (4.26%) NS
20 (33.33%) 13 (19.7%) 12 (25.53%) NS
3 3,75 3,25 NS
5 (8.33%) 10 (15.15%) 2 (4.26%) NS
9 (15%) 4 (6.06%) 2 (4.26%) NS
16 (26.67%) 10 (15.15%) 5 (10.64%) NS
mHg 11 (18.33%) 6 (9.09%) 5 (10.64%) NS
3 (5%) 1 (1.52%) 2 (4.26%) NS
51 (86.44%) 58 (89.23%) 39 (82.98%) NS
8 (13.66%) 8 (10.76%) 7 (17.02%) NS
15 (25%) 11 (16.67%) 12 (25.53%) NS
101.5 106 101 NS
22 (37.3%) 23 (34.8%) 19 (41.3%) NS
37 (62.7%) 43 (65.2%) 27 (58.7%)
23 (39%) 24 (36.4%) 19 (41.3%) NS
36 (61%) 42 (63.6%) 27 (58.7%)
45 (77.59%) 46 (71.88%) 35 (76.09%) NS
44 (73.33%) 53 (79.1%) 39 (82.98%) NS
40 (67.8%) 47 (73.44%) 35 (77.78%) NS
39 (67.24%) 48 (73.85%) 31 (67.39%) NS
27 (46.55%) 23 (37.1%) 28 (63.64%) 0.026
9 (15.52%) 8 (12.9%) 12 (26.09%) NS
5 (20%) 7 (22.58%) 8 (42.11%) NS
4 (16.67%) 8 (27.59%) 7 (36.84%) NS
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Descriptive analysis data are presented as n (%) for
categorical variables, and as median (interquartile range
[IQR]) for continuous variables (after non-normal distri-
bution was shown), as appropriate. Baseline characteristics
of CAP patients were compared among the three groups
together using ANOVA analysis or Kruskal-Wallis H test
depending on the type of variable. Comparisons, except
for baseline characteristics, were established between two
different groups. In order to compare the values of everyTable 2 Microbial etiologies of the 171 cases of CAP included
Bacterial n: Viral
S pneumoniae 29 Adenovirus
E coli 3 Influenza virus A
Legionella pneumophila 4 Rhinovirus
SARM 3 Coronavirus
H influenzae 2 RSV-A
Corynebacterium striatum 2 RSV-B
Serratia marcescens 1 Influenza virus B
Moraxella catarrhalis 1 Metapneumovirus
Alcaligenes xylosoxidans 1 Influenza virus A + Influenza virus
Enterobacter cloacae 1 Influenza virus A + Parainfluenza 1
S pneumoniae + H influenzae 2 Influenza virus A + RSV-A
S pneumoniae + S aureus 2 Influenza virus A + H1N1
S pneumoniae + P aeruginosa 1 Influenza virus A + Coronavirus
P aeruginosa + Legionella 1 Influenza virus A + Rhinovirus
P aeruginosa + C striatum 1 Influenza virus A + Adenovirus
P aeruginosa + S marcescens + H
influenzae
1 Influenza virus A + RSV +Metapne
E coli + Corynebacterium striatum +
A baumannii
1 Influenza virus A + RSV + V. influen
E coli + Achromobacter xylosoxidans 1 Adenovirus + RSV-A
S aureus + Enterococcus faecium 1 Adenovirus + Parainfluenza 3
S aureus + Pasteurella multocida 1 Adenovirus + Rhinovirus
Adenovirus + Coronavirus
Adenovirus + Influenza virus B + R
Adenovirus + Enterovirus + Corona
Rhinovirus + Influenza virus B
Rhinovirus + Cox virus
Coronavirus + RSV-A
Parainfluenza 1 + H1N1
Cox virus + Enterovirus
TOTAL 59 TOTALbiomarker between the different etiologic groups, two-
group comparisons were performed using the Mann–
Whitney U-test. For every biomarker the two-group
comparisons performed were: bacterial vs mixed; bacterial
vs viral; mixed vs viral; mixed vs overall bacterial and viral;
and mixed vs unknown. P-values <0.05 were considered
to indicate statistical significance.
A large number of univariate and multivariate logistic
regression analyses were performed to investigate the fac-
tors associated with mixed viral-bacterial CAP, includingin the study
n: Mixed n:
10 S pneumoniae + Adenovirus 5
9 S pneumoniae + Rhinovirus 6
9 S pneumoniae + Influenza A 4
7 S pneumoniae +Metapneumovirus 2
3 S pneumoniae + Influenza B 1
1 S pneumoniae +Moraxella catarrhalis + Influenza
virus A
1
1 S pneumoniae + S aureus + Adenovirus 1
1 S pneumoniae + H influenzae + Adenovirus +
Rhinovirus + Cox virus
1
B 2 S pneumoniae + Rhinovirus + Influenza A 1
1 S pneumoniae + Rhinovirus + Cox virus 2
1 S pneumoniae + Rhinovirus + H1N1 1
1 S pneumoniae + Adenovirus + Coronavirus 1
1 S pneumoniae + Influenza virus A + Parainfluenza 4 1
1 S pneumoniae + Influenza virus A + RSVA 1
1 S pneumoniae + Influenza virus A + Coronavirus 1
umovirus 2 S pneumoniae + Rhinovirus + Coronavirus +
Enterovirus
1
za B 1 S pneumoniae + Coronavirus + Influenza v. A +
Influenza v. B + RSV
1
1 S pneumoniae + RSVB 2
1 H influenzae + Parainfluenza 3 1
1 H influenzae + Adenovirus + H1N1 1
1 H influenzae + Adenovirus + Rhinovirus 1
SV 1 H influenzae + Rhinovirus + RSVA 1
virus 1 P aeruginosa + H1N1 1
1 P aeruginosa + Rhinovirus 1
3 P aeruginosa + RSVA + Coronavirus 1
2 P aeruginosa + RSVB 1
1 E coli + Influenza virus B + Rhinovirus 1
1 E coli + Influenza virus A + RSV 1
Moraxella catarrhalis + Coronavirus 1
Corynebacterium striatum +Metapneumovirus 1
Stenotrophomonas maltophilia + Adenovirus 1
66 TOTAL 46
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diabetes, COPD), clinical (fever, dyspnea, pleuritic pain,
purulent sputum) and radiological data (type of infil-
trate, number of lobes involved), severity scores (PSI
and CURB65), and biomarkers (PCT, CRP and WBC).
The best model was selected by a stepwise procedure.
We constructed receiver operating characteristic (ROC)
curves and determined the area under the curve (AUC).
The AUC and its 95% confidence intervals were estimated
for each biomarker to predict different CAP etiologies
(bacterial, viral, mixed, and bacterial-involved) and
compared using a nonparametric method. Sensitivity,
specificity, positive and negative predictive values, and
positive and negative likelihood ratios (LHR + and LHR-,
respectively) were calculated for each cut-off value of the
biomarkers.
Statistical analysis was performed using the SPSS
statistical software package, version 15.0. The level of
significance for all statistical tests was a 2-sided, p value
of 0.05.Table 3 Median (interquartile range) levels of biomarkers
in CAP and control groups
Biomarkers PCT CRP WBC
Cohort (ng/mL) (mg/dL) (103/μL)
Control 0.06 (0.08) 1.60 (6.61) 7.90 (3.10)
(n = 100) (n = 100) (n = 97)
CAP 0.90 (4.35) 18.50 (21.92) 12.60 (8.20)
(n = 169) (n = 171) (n = 171)
p-value <0.001 <0.001 <0.001Results
Patients and controls
We selected 280 patients from those admitted to the
emergency department due to CAP, after excluding those
who did not meet inclusion criteria, those without a com-
prehensive microbiological study and those with a final
diagnosis other than CAP on discharge. A total of 185
cases were finally selected. The Figure 1 shows a flowchart
explaining the process of enrollment of patients. Our final
three groups were as follows: 59 (34.6%) bacterial, 66
(38.5%) viral and 46 (26.9%) mixed viral-bacterial CAP,
and their main clinical characteristics are summarized in
Table 1. Ninety five patients had a negative microbio-
logical study, and 3 of them had no biomarker results (92
of unknown cause).
Patients were distributed, according to PSI and CURB65
scores, as severe (PSI 4–5 and/or CURB65 2–5) and non-
severe (PSI 1–3 and/or CURB65 0–1). Severe bacterial
CAP included 38/59 (PSI) and 36/59 (CURB65); viral
CAP, 43/66 (PSI) and 40/66 (CURB65); and mixed, 28/46
(PSI) and 29/46 (CURB65) patients. No differences were
found for either clinical score (p = 0.831 for PSI and 0.950
for CURB65) when proportions of severe and non-severe
CAP were compared in the three groups.
After excluding atypical and low-pathogenicity bac-
teria, we selected 174 patients with viral, bacterial and
mixed CAP. A biomarker search could not be per-
formed in 3 patients, and we finally included 171
(61%) patients in our study with both etiology and bio-
markers (see Figure 1). Of these, one patient from the
viral group and another from the mixed group lacked
PCT determination.Microbial etiology
Etiological agents isolated in each group are shown in
Table 2. With the exception of atypical serology, every
patient underwent all diagnostic tests. Streptococcus
pneumoniae was the most frequent agent associated
with CAP [67/280, 23.9% (67/171, 39.2% of CAP of
known etiology)] and was found in 34/59 (57.6%) pa-
tients in the bacterial group: 29 as a single microorgan-
ism and 5 in association with other bacteria. It was also
identified in 33/46 (71.7%) of mixed bacterial/viral eti-
ologies, in which the most prevalent associations were S
pneumoniae with rhinovirus (12), influenza A (10), and
adenovirus (8). In the viral CAP group, the most fre-
quently isolated pathogens were Influenza A (21), adeno-
virus (17) and rhinovirus (15). Of 67 cases of pneumonia
in which S pneumoniae was isolated, 33/67 (49.2%) were
associated with viruses.
Viruses were involved in 40% [(112/280) and 65.5%
(112/171) of cases of CAP with established cause (ex-
cluding atypical)], whereas 46/280 (16.4%) and 46/171
(26.9%) of those of known etiology had a mixed
bacterial-viral etiology. This information is summa-
rized in Table 2.
The control group was composed of 100 subjects
matched for age and sex. Comorbidities in this group
were similar to those of CAP patients. Biomarker levels
were checked in all of them. Nasopharyngeal aspirates
were obtained in 60 of the subjects for viral searches,
including both PCR tests. Paired blood samples for
serological studies were not obtained in these subjects.
In the control group, 4 viruses (3 adenovirus and 1 para-
influenza 4) were isolated in 4 subjects (4/60, 6.7%).
PCT, CRP and WBC were significantly higher in CAP
patients than in the controls, as shown in Table 3.
Biomarkers and etiology
Bacterial and mixed CAP showed no differences for
PCT (p = 0.416). Viral CAP had significantly lower PCT
values than both bacterial and mixed (p = 0.02 and 0.007,
respectively). CRP was significantly higher in mixed CAP
than in bacterial (p = 0.027) and viral (p = 0.005) CAP, and
there were no differences between the latter two groups
Table 4 Biomarker values in different etiologic groups of CAP
Bacterial Mixed Viral Unknown p
N Median Interquartile
range
N Median Interquartile
range
N Median Interquartile
range
N Median Interquartile
range
Bacterial
vs Mixed
Bacterial
vs Viral
Mixed
vs Viral
Mixed vs
Overall bacterial
and viral
Mixed vs
Unknown
PCT (ng/mL) 59 1,37 4,635 45 1,978 8,324 65 0,38 1,756 92 0.18 0.899 0,416 0,02 0,007 0,044 0.002
CRP (mg/dL) 59 18 21,64 46 28,19 28,15 66 14,535 15,14 92 17.10 18.165 0,027 0,614 0,005 0,004 0.001
WBC (cells/mm3) 59 13,4 7,2 46 12,05 8,7 66 11,6 8,1 92 11.90 7.900 0,235 0,109 0,866 0,588 0.676
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Figure 2 Median procalcitonin (PCT) and C reactive protein (CRP) values for bacterial, viral and mixed CAP.
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higher values in mixed group compared to overall viral
and bacterial CAP, and to those with unknown cause.
WBC counts in bacterial, mixed and viral CAP showed
no differences among the three groups (p > 0.05) (Table 4).
See Figure 2.
PCT, CRP and WBC showed similar results in influ-
enza CAP and non-influenza viral CAP (p = 0.299, 0.345
and 0.091, respectively) (Table 5). When influenza A and
B were removed from viral (n = 25) and mixed (n = 15)
groups, PCT and CRP levels showed significantly higher
levels in mixed CAP compared to viral CAP without in-
fluenza (p = 0.019 and 0.046, respectively). WBC showed
no differences in either biomarker (Table 6). CRP levels
were also higher in mixed involving influenza than in
viral CAP due to influenza virus (Table 7).
To differentiate mixed from overall bacterial and viral
CAP, a cut-off of CRP of 25.95 mg/dL, near our median
values, showed a PPV of 0.45 (95% CI, 0.32-0.58) and an
NPV of 0.83 (0.76-0.9).
With regard to PCT, a cut-off of 2.10 ng/mL (near our
median values) discriminated bacterial-involved (bacter-
ial and mixed) from viral CAP with a positive predictive
positive value (PPV) of 0.78 (95% confidence interval
[CI], 0.68-0.88) and a negative predictive value (NPV) of
0.48 (95% CI, 0.38-0.57).Table 5 Biomarkers values in influenza and viral without influ
Biomarkers Viral without influenza
N Median Interquartile range
PCT (ng/mL) 40 0,388 1,656
CRP (mg/dL) 41 14,200 13,880
WBC (cells/mm3) 41 12,900 7,600A large number of univariate and multivariate logistic
regression analyses were performed to investigate the
factors associated with mixed viral-bacterial CAP. The
final multivariate logistic regression model selected by a
stepwise procedure included only one independent vari-
able, the CRP that was the only independent factor associ-
ated with mixed etiology. The other parameters showed
no association with viral-bacterial CAP after adjusting for
the rest of variables (Table 8).
Receiver operating characteristic (ROC) analysis for PCT
to discriminate bacterial-involved (bacterial and mixed)
from viral CAP showed an area under curve (AUC) of
0.640 (p = 0.002). The AUC was 0.621 (p = 0.02) for dis-
criminating between bacterial and viral CAP, and 0.651
(p = 0.007) for discriminating between mixed and viral
CAP. The CRP AUC for discriminating between bacterial-
involved and viral CAP was not significant (0.579, p = 0.081),
but there were differences between mixed and bacterial
(0.626, p = 0.027), mixed and viral (0.657, p = 0.005), and
mixed and overall bacterial and viral (0.642, p = 0.004)
(Table 9). See Figures 3 and 4.Discussion
The main conclusions of our study are that biomarkers
in adult, immunocompetent, mixed viral-bacterial CAPenza CAP
Influenza p
N Median Interquartile range
25 0,380 4,285 0,299
25 15,580 13,720 0,345
25 10,700 6,700 0,091
Table 6 Biomarker values in mixed and viral CAP, after removing influenza virus
Mixed without influenza Viral without influenza p
N Median Interquartile range N Median Interquartile range
PCT (ng/mL) 30 2,0545 9,407 40 0,388 1,656 0,019
CRP (mg/dL) 31 26,8 31,4 41 14,200 13,880 0,046
WBC (cells/mm3) 31 12,7 10,4 41 12,900 7,600 0,798
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viral CAP, as follows:
A)Mixed CAP had similar PCT levels to bacterial CAP
but different from viral CAP, and CRP levels were
higher in mixed than in either bacterial or viral CAP
(Table 4). PCT and CRP levels were higher in mixed
than overall viral and bacterial group, and than CAP
of unknown cause (Table 4). These differences were
not associated with a different severity.
B) PCT levels above 2.10 ng/mL on admission may
indicate bacterial-involved pneumonia (bacterial
or mixed viral-bacterial) with a high probability
(78%). Elevated CRP levels was the only independent
factor associated with mixed etiology, and a value
below 25.95 mg/mL ruled out mixed etiology with
83% probability.
In recent years, some studies have shown the import-
ance of mixed viral-bacterial pneumonia, reporting a
prevalence of 4%-28% of CAP in adults, and 11%-39% of
CAP with known etiology (1–7). These wide ranges are
due to different study designs and, especially, to the num-
ber and type of diagnostic techniques used. In our study
we included every test commonly used in clinical practice,
as well as two different PCR assays for respiratory viruses,
as these techniques are not standardized, in order to ob-
tain the most complete virus yield possible. By following
this protocol, we were able to identify a very definite
group of mixed pneumonia and compare it to pure bacter-
ial and viral groups.
The importance of mixed CAP has been recognized in
recent years, and has been clearly underestimated so far.
Some studies have found these types of CAP to be more
severe than bacterial CAP [2,7,23], whereas others, like
our study, found no differences in etiology-related severityTable 7 Biomarker values in influenza and mixed with influen
Influenza
N Median Interquartile range
PCT (ng/mL) 25 0,376 4,674
CRP (mg/dL) 25 15,580 13,720
WBC (cells/mm3) 25 10,700 6,700[5,6]. The importance of suspecting mixed CAP is justified
because these cases can be more severe and some of the
viruses isolated can be treated.
Most mixed bacterial-viral CAP had pneumococcus as
the causative agent, and half of our S pneumoniae pneu-
monias were associated with viruses. These data indicate
that many cases of CAP usually considered pneumococ-
cal CAP, are in reality mixed viral-bacterial infections,
because viruses are not usually looked for. Conversely,
when viral PCR is used, many considered as viral CAP
can be in reality mixed, with missed bacteria [3].
It is true that a viral genome may be isolated from the
upper airways of some asymptomatic subjects and, there-
fore, in patients with CAP, this may suggest previous or
concomitant upper respiratory viral infection unrelated to
the pneumonia. A study including BAL in severe CAP
found that a viral genome was identified in upper respira-
tory samples without its alveolar isolation in only 13% of
cases [24], and we only identified a virus in 6.7% in our
controls, similar to other studies [4]. Not all authors are
clear as to whether viruses other than influenza can, by
themselves, cause pneumonia in adults or whether they
must act in conjunction with other respiratory pathogens
[2,3,6-8]. Rhinovirus was the most common virus identi-
fied in BAL of patients with severe CAP in a recent
study [24], and our data showing a different inflamma-
tory response of pure viral pneumonia compared with
those of bacterial-viral CAP also suggest that viruses,
other than influenza, can, by themselves, cause pneu-
monia in adult patients.
There is information in the literature confirming that
viral pneumonia induces a different biomarker response
compared to bacterial pneumonia. In fact, other studies
have confirmed these differences also including atypicals
[11-13]. The lack of PCT response to viral disease seems
to be due to stimulation of macrophages to releaseza CAP
Mixed with influenza p
N Median Interquartile range
15 1,880 4,001 0,315
15 31,710 24,600 0,035
15 11,100 9,000 0,679
Table 8 Uni and multivariate logistic regression analysis for mixed etiology
Variable Univariate Multivariate
p -value* OR IC 95% p -value* OR IC 95%
Age 0,447 0,992 0,971 1,013
Sex 0,055 0,514 0,261 1,014
PSI 0,568 0,819 0,412 1,628
CURB65 0,789 1,100 0,547 2,211
Diabetes 0,240 0,563 0,216 1,469
Chronic hepatopathy 0,716 0,663 0,072 6,089
Chronic renal failure 0,817 0,881 0,301 2,575
Heart failure 0,311 0,689 0,335 1,418
Cerebrovascular disease 0,456 0,707 0,283 1,765
No. Of days of symptom 0,772 1,010 0,945 1,080
Fever 0,842 1,084 0,492 2,390
Purulent sputum 0,122 1,751 0,861 3,561
Dyspnea 0,674 0,855 0,413 1,772
Pleuritic pain 0,014 2,450 1,200 5,000 >0.05
No. lobes involved 0,401 1,491 0,587 3,788
COPD 0,429 0,737 0,346 1,569
PCT (ng/ml) 0,019 1,069 1,011 1,130 >0.05
CRP (mg/dl) 0,002 1,040 1,014 1,067 0,002 1,040 1,014 1,067
WBC 0,966 0,999 0,949 1,051
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synthesis that, in turn, is necessary for tissues to
synthesize PCT [15]. In our study, PCT levels were simi-
lar in mixed and bacterial CAP, and higher than those of
viral CAP, and in terms of CRP, we found that mixed
CAP showed significantly higher levels than bacterial
and viral pneumonias. This biomarker was the only
independent factor associated with mixed etiology. The
high NPV for CRP, can help us to suspect an aetiologyTable 9 Results of receiver operating characteristic (ROC)
analysis for PCT and CRP for discrimination among
etiologies
PCT AUC 95% CI Significance
Bacterial-involved (bacterial and
mixed) vs viral
0.640 0.557-0.723 p = 0.002
Bacterial vs viral 0.621 0.522-0.720 p = 0.02
Mixed vs viral 0.651 0.544-0.758 p = 0.007
CRP AUC 95% CI Significance
Bacterial-involved (bacterial and
mixed) vs viral
0.579 0.494-0.665 NS
Mixed vs bacterial 0.626 0.514-0.738 p = 0.027
Mixed vs viral 0.657 0.546-0.768 p = 0.005
Mixed vs overall bacterial and viral 0.642 0.537-0.747 p = 0.004different than mixed bacterial/viral. However, it is true
that its low PPV and AUC limit its usefulness in the
clinical setting.
Some studies have suggested a potential role of bio-
markers in differentiating pandemic influenza A H1N1
CAP from its bacterial coinfection. All these studies were
retrospective and involved a limited number of mainly
critical (ICU) patients (the largest series included 19 cases
of mixed CAP), and found lower levels of PCT [16] and of
PCT and CRP [18,19] in viral CAP than mixed H1N1-
bacterial CAP, as well as their utility in clinical practice
[16,18,19]. However, others showed limited sensitivity and
specificity [17]. We also found a serum CRP higher in
mixed infections involving influenza, but differences could
not be achieved for PCT, probably due to low number of
our cases (n = 15). With the exception of influenza, there
is no information in adults on the behavior of biomarkers
in mixed pneumonia. In our study, we found that the in-
flammatory response was higher in mixed CAP compared
to single bacterial and viral CAP. We included mixed
viral-bacterial CAP not restricted to the influenza virus in
a homogeneous adult group of patients, and both PCT
and CRP were different in viral CAP without influenza
than mixed CAP without influenza.
The ability of CRP to discriminate mixed viral-bacterial
CAP from bacterial CAP was considered limited in
Figure 3 Receiving operating characteristic curve of PCT for
differentiating bacterial-involved (bacterial and mixed) from
viral CAP. AUC: 0.640, 95% CI: 0.557-0.723. p = 0.002.
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cases of mixed CAP in adults that included two or
more typical or atypical bacteria, and combinations of
typical with atypical and any bacteria with virus, in
which PCT and CRP levels were tested together [10].
Although increased amounts of biomarkers, especiallyFigure 4 Receiving operating characteristic curve of CRP for
differentiating mixed from bacterial and viral CAP. AUC: 0.642,
95% CI: 0.537-0.747. p = 0.004.PCT, have been associated with increased pneumonia
severity [10], this was not the case in our study, as we
found no differences in either PSI or CURB56 scores
among three etiological groups. Median CRP was high-
est in mixed CAP, perhaps reflecting an increased level
of systemic inflammation, as has been suggested [7]. It
is difficult to explain with accuracy why mixed CAP
showed higher CRP levels than both viral and bacterial
pneumonias. It has recently been suggested that the
main etiological agents of CAP present different in-
flammatory profiles, according to their respective bio-
marker (CRP, PCT, TNF-α, and IL-6) response, and
that host-microorganism interplay may be useful for
etiological diagnosis [11]. Our results suggest that
mixed bacterial/viral CAP have a predominant CRP re-
sponse. Findings of investigations approaching useful-
ness of PCT and CRP for etiological diagnosis of CAP
are contradictory [25]. This can be due, at least in
part, to the lack of inclusion of mixed bacterial/viral
pneumonias in these studies.
There were no differences in WBC counts among the
three etiological groups.
Our study is subject to certain limitations. This is a
study from a single hospital, with a limited number of
patients. We obtained no lower respiratory tract samples
(BAL) for viral study, and some of the nasopharyngeal
viral findings may have come from concomitant viral
upper respiratory infection. We did not use PCR tech-
niques for diagnosing atypical bacteria, and our yield for
these pathogens, based in serological testing, was low.
Nevertheless, our purpose was to study viruses and bac-
teria, and atypical findings were excluded. We are aware
that some pneumonias classified as viral could, in fact,
have been mixed, with a bacteria that could not be iden-
tified without a quantified PCR test for bacteria. Finally,
a sequential search for biomarkers might have given us
more complete information. The major strength of our
study is that we compared a very well defined population
of mixed CAP to other groups of very well defined bac-
terial and viral CAP.
Conclusions
Our findings suggest a specific inflammatory profile in
mixed viral-bacterial CAP, which is different from that
of both bacterial and viral CAP. These findings can be
useful by clinicians to include antiviral treatment espe-
cially during the influenza season, and to suspect a bac-
terial role in the case of either symptoms suggesting
virus involvement or viral isolation. Interestingly our re-
sults were similar when we excluded mixed influenza
cases. This is the first study to assess biomarkers in a
group of mixed viral-bacterial CAP other than influenza,
and compared with bacterial and viral adult CAP. The
biomarker profile in this group is different from that of
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http://www.biomedcentral.com/1471-2466/14/123viral CAP. This suggests that the inflammatory response
to viruses, even excluding influenza, is different from
that in mixed CAP and, therefore, that viruses do not
always require a bacterial co-pathogen to produce pneu-
monia in adults. This may help us better understand the
true role of viruses in CAP and, perhaps, encourage the
development of effective antiviral drugs [8]. Despite their
usefulness in some particular cases, we appear to lack an
accurate biomarker to separate bacterial-involved CAP
from viral CAP in clinical practice.
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